Botulinum toxin type A

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Nervous System Disorders

Conditions

Nervous System Disorders

Trial Timeline

Nov 1, 2011 → Dec 1, 2014

NCT ID

NCT01313312

About Botulinum toxin type A

Botulinum toxin type A is a phase 3 stage product being developed by Ipsen for Nervous System Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT01313312. Target conditions include Nervous System Disorders.

What happened to similar drugs?

0 of 7 similar drugs in Nervous System Disorders were approved

Approved (0) Terminated (0) Active (7)

🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3

🔄temozolomideMerckPhase 3

🔄leflunomide + procarbazine hydrochloridePfizerPhase 3

🔄Gadobutrol (Gadavist, Gadovist, BAY86-4875) + MagnevistBayerPhase 3

🔄Gadobutrol (Gadavist, Gadovist, BAY86-4875)BayerPhase 3

🔄Botulinum toxin type A + Botulinum toxin type A + PlaceboIpsenPhase 3

🔄EryDex Low dose DSP + EryDex High dose DSP + Pooled PlaceboQuince TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03017729	Pre-clinical	Completed	Feb 10, 2017	Nov 30, 2020	Lower Limb Spasticity
NCT02969356	Approved	Completed	Dec 18, 2016	Jul 1, 2018	Spastic Hemiparesis
NCT02020980	Pre-clinical	Completed	Apr 1, 2014	Mar 5, 2018	Lower Limb Spasticity
NCT02106351	Phase 3	Completed	Apr 1, 2014	Sep 4, 2018	Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
NCT01753336	Phase 3	Completed	Mar 1, 2013	Oct 1, 2015	Cervical Dystonia
NCT01753349	Pre-clinical	Completed	Dec 1, 2012	Sep 25, 2017	Cervical Dystonia
NCT01682148	Phase 3	Terminated	Sep 1, 2012	Mar 1, 2015	Arm Spasticity
NCT01313312	Phase 3	Completed	Nov 1, 2011	Dec 1, 2014	Nervous System Disorders
NCT01251380	Phase 3	Completed	Oct 1, 2011	Jan 1, 2015	Cerebral Palsy
NCT01251367	Phase 3	Completed	Jun 1, 2011	Apr 1, 2015	Post-stroke Spasticity
NCT00455637	Phase 2	Terminated	Mar 1, 2007	Mar 17, 2008	Cerebral Palsy
NCT00288509	Phase 3	Completed	Feb 1, 2006	Jan 1, 2008	Cervical Dystonia
NCT00276315	Phase 3	Completed	Dec 1, 2005	Jan 1, 2007	Hemifacial Spasm
NCT00246142	Phase 3	Completed	Apr 1, 2005	Jun 27, 2007	Myofascial Pain Syndromes
NCT00134810	Phase 2	Completed	Mar 1, 2005	May 18, 2006	Myofascial Pain Syndromes
NCT00149240	Phase 2	Completed	Jan 1, 2005	Feb 2, 2006	Myofascial Pain Syndromes
NCT00246155	Phase 3	Completed	Jan 1, 2005	Jul 1, 2005	Low Back Pain
NCT00447772	Phase 3	Completed	Oct 1, 2004	Apr 1, 2008	Cervical Dystonia
NCT00247559	Phase 2	Completed	May 1, 2004	Apr 8, 2005	Lateral Canthal Lines
NCT00210444	Phase 2	Completed	Jun 1, 2003	Dec 1, 2006	Anal Fissure

Competing Products

20 competing products in Nervous System Disorders

See all competitors

Product	Company	Stage	Hype Score
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	29
Methotrexate + Ibrutinib + Temozolomide	Sun Pharmaceutical	Phase 2	31
alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcohol	Eisai	Phase 1	29
perampanel	Eisai	Phase 2	35
Tirabrutinib + Placebo	Ono Pharmaceutical	Phase 2	42
Tirabrutinib	Ono Pharmaceutical	Phase 1	36
ONO-4059 + Rituximab + Methotrexate + Procarbazine + Vincristine	Ono Pharmaceutical	Phase 1	33
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	47
Tirabrutinib + Tirabrutinib + Tirabrutinib	Ono Pharmaceutical	Phase 2	39
pemetrexed	Eli Lilly	Phase 1	29
HRS-9231 + Gadobutrol	Jiangsu Hengrui Medicine	Phase 2	42
Acalabrutinib	AstraZeneca	Phase 2	39
Durvalumab + Acalabrutinib	AstraZeneca	Phase 1	33
Avelumab + Lenvatinib	Merck	Phase 1	33
temozolomide	Merck	Phase 3	44
Ibrutinib + Pembrolizumab + Rituximab	Merck	Phase 1/2	39
Temozolomide	Merck	Phase 2	35
AEE788 + everolimus	Novartis	Phase 1/2	32
vatalanib	Novartis	Phase 2	35
EPO906 (epothilone B)	Novartis	Phase 1	29